%0 Journal Article %A CURRY L. KOENING %A JOSÉ HERNÁNDEZ-RODRÍGUEZ %A EAMONN S. MOLLOY %A TIFFANY M. CLARK %A GARY S. HOFFMAN %T Limited Utility of Rapamycin in Severe, Refractory Wegener’s Granulomatosis %D 2009 %R 10.3899/jrheum.080664 %J The Journal of Rheumatology %P 116-119 %V 36 %N 1 %X Objective We report our experience using rapamycin in patients with Wegener’s granulomatosis (WG) who failed to achieve remission with conventional treatment. Methods Eight patients received rapamycin for severe, refractory WG. Clinical outcomes were reviewed retrospectively. Results Four patients treated with rapamycin sustained remissions of at least 6 months’ duration while receiving prednisone ≤ 10 mg/day; 2 relapsed during followup. Five patients discontinued rapamycin due to continued disease activity, cancer, or adverse events. Conclusion Toxicities due to rapamycin were numerous; consistent proof of efficacy in this pilot experience with WG was not seen. %U https://www.jrheum.org/content/jrheum/36/1/116.full.pdf